

Cardiology

Expertise in cardiomyopathy and heart failure clinical trial delivery

Non-Obstructive & Obstructive Hypertrophic Cardiomyopathy Dilated Cardiomyopathy • Transthyretin Amyloidosis with Cardiomyopathy HFpEF • HFrEF | Acute Heart Failure

The PPD™ clinical research business of Thermo Fisher Scientific is dedicated to working closely with our client partners to advance their treatments for heart failure and cardiomyopathy. Our experienced team of professionals are adept at navigating the unique landscape of cardiomyopathy & rare disease trials:

- Cardiomyopathy and heart failure **adept study teams**, including **6 in house cardiologists, of which 4 are experienced heart failure specialists**. We understand the medical, clinical and regulatory requirements for cardiomyopathy and heart failure clinical trials.
- Using our extensive global database and proven working relationships with cardiomyopathy and heart failure experts and treatment centers around the globe, **we identify and engage the right sites** for your clinical trial
- We are **the only CRO** providing dedicated expertise at the **study level** to optimize clinical development **programs for diversity**
- Our project teams have robust global eCOA implementation experience with dedicated Digital Project Managers to facilitate the process from start to finish
- We understand the **physical and emotional toll cardiomyopathy and/or heart failure** can have on **patients** with this diagnosis. Our team will work to employ **innovative solutions** that both **enhance patient recruitment** and **reduce patient burden** to support a positive patient experience and limit loss of data due to patient withdrawal
- **Strong experience** with modalities to collect robust data and monitor safety, including **echocardiography** central review, **CMR, CPET, eCOA, ECG, holter monitors/ wearable devices** and more
- Robust **understanding** of **vendor/ARO core laboratory operations**

Past 5-year experience

Cardiomyopathy

- **19** Phase I-IV cardiomyopathy studies supported:
 - ATTR Cardiomyopathy
 - 7 Hypertrophic Cardiomyopathy
 - 2 Dilated Cardiomyopathy
- **740+** sites activated across 44 countries
- **4100+** patients enrolled

Heart failure

- **7** Phase I, II, & IV heart failure studies supported
- **265+** sites activated across 20 countries
- **475+** patients enrolled



Scan to
learn
more

Learn more at ppd.com

ppd